583 related articles for article (PubMed ID: 29160817)
1. Impact of High-Dose Multi-Strain Probiotic Supplementation on Neurocognitive Performance and Central Nervous System Immune Activation of HIV-1 Infected Individuals.
Ceccarelli G; Brenchley JM; Cavallari EN; Scheri GC; Fratino M; Pinacchio C; Schietroma I; Fard SN; Scagnolari C; Mezzaroma I; Vullo V; d'Ettorre G
Nutrients; 2017 Nov; 9(11):. PubMed ID: 29160817
[TBL] [Abstract][Full Text] [Related]
2. A pilot study on the effects of probiotic supplementation on neuropsychological performance and microRNA-29a-c levels in antiretroviral-treated HIV-1-infected patients.
Ceccarelli G; Fratino M; Selvaggi C; Giustini N; Serafino S; Schietroma I; Corano Scheri G; Pavone P; Passavanti G; Alunni Fegatelli D; Mezzaroma I; Antonelli G; Vullo V; Scagnolari C; d'Ettorre G
Brain Behav; 2017 Aug; 7(8):e00756. PubMed ID: 28828217
[TBL] [Abstract][Full Text] [Related]
3. Persistent central nervous system immune activation following more than 10 years of effective HIV antiretroviral treatment.
Ulfhammer G; Edén A; Mellgren Å; Fuchs D; Zetterberg H; Hagberg L; Nilsson S; Yilmaz A; Gisslén M
AIDS; 2018 Sep; 32(15):2171-2178. PubMed ID: 30005007
[TBL] [Abstract][Full Text] [Related]
4. Viral and inflammatory markers in cerebrospinal fluid of patients with HIV-1-associated neurocognitive impairment during antiretroviral treatment switch.
Tiraboschi JM; Muñoz-Moreno JA; Puertas MC; Alonso-Villaverde C; Prats A; Ferrer E; Rozas N; Maso M; Ouchi D; Martinez-Picado J; Podzamczer D
HIV Med; 2015 Jul; 16(6):388-92. PubMed ID: 25721471
[TBL] [Abstract][Full Text] [Related]
5. Challenges in the management of HIV infection: update on the role of probiotic supplementation as a possible complementary therapeutic strategy for cART treated people living with HIV/AIDS.
Ceccarelli G; Statzu M; Santinelli L; Pinacchio C; Bitossi C; Cavallari EN; Vullo V; Scagnolari C; d'Ettorre G
Expert Opin Biol Ther; 2019 Sep; 19(9):949-965. PubMed ID: 31260331
[No Abstract] [Full Text] [Related]
6. Elevated cerebrospinal fluid Galectin-9 is associated with central nervous system immune activation and poor cognitive performance in older HIV-infected individuals.
Premeaux TA; D'Antoni ML; Abdel-Mohsen M; Pillai SK; Kallianpur KJ; Nakamoto BK; Agsalda-Garcia M; Shiramizu B; Shikuma CM; Gisslén M; Price RW; Valcour V; Ndhlovu LC
J Neurovirol; 2019 Apr; 25(2):150-161. PubMed ID: 30478799
[TBL] [Abstract][Full Text] [Related]
7. Progressive increase in central nervous system immune activation in untreated primary HIV-1 infection.
Suh J; Sinclair E; Peterson J; Lee E; Kyriakides TC; Li FY; Hagberg L; Fuchs D; Price RW; Gisslen M; Spudich S
J Neuroinflammation; 2014 Dec; 11():199. PubMed ID: 25465205
[TBL] [Abstract][Full Text] [Related]
8. Low levels of HIV-1 RNA detected in the cerebrospinal fluid after up to 10 years of suppressive therapy are associated with local immune activation.
Dahl V; Peterson J; Fuchs D; Gisslen M; Palmer S; Price RW
AIDS; 2014 Sep; 28(15):2251-8. PubMed ID: 25022595
[TBL] [Abstract][Full Text] [Related]
9. Persistent intrathecal immune activation in HIV-1-infected individuals on antiretroviral therapy.
Yilmaz A; Price RW; Spudich S; Fuchs D; Hagberg L; Gisslén M
J Acquir Immune Defic Syndr; 2008 Feb; 47(2):168-73. PubMed ID: 17971711
[TBL] [Abstract][Full Text] [Related]
10. Probiotics Differently Affect Gut-Associated Lymphoid Tissue Indolamine-2,3-Dioxygenase mRNA and Cerebrospinal Fluid Neopterin Levels in Antiretroviral-Treated HIV-1 Infected Patients: A Pilot Study.
Scagnolari C; Corano Scheri G; Selvaggi C; Schietroma I; Najafi Fard S; Mastrangelo A; Giustini N; Serafino S; Pinacchio C; Pavone P; Fanello G; Ceccarelli G; Vullo V; d'Ettorre G
Int J Mol Sci; 2016 Sep; 17(10):. PubMed ID: 27689995
[TBL] [Abstract][Full Text] [Related]
11. (1→3)-β-D-Glucan Levels Correlate With Neurocognitive Functioning in HIV-Infected Persons on Suppressive Antiretroviral Therapy: A Cohort Study.
Hoenigl M; de Oliveira MF; Pérez-Santiago J; Zhang Y; Morris S; McCutchan AJ; Finkelman M; Marcotte TD; Ellis RJ; Gianella S
Medicine (Baltimore); 2016 Mar; 95(11):e3162. PubMed ID: 26986173
[TBL] [Abstract][Full Text] [Related]
12. Cerebrospinal fluid extracellular vesicles and neurofilament light protein as biomarkers of central nervous system injury in HIV-infected patients on antiretroviral therapy.
Guha D; Mukerji SS; Chettimada S; Misra V; Lorenz DR; Morgello S; Gabuzda D
AIDS; 2019 Mar; 33(4):615-625. PubMed ID: 30557159
[TBL] [Abstract][Full Text] [Related]
13. Antiviral Activity of Fecal Water Samples from HIV-1 Infected Subjects Treated with a Specific Probiotic Formulation.
Falasca F; Cavallari EN; Innocenti GP; Scagnolari C; Mezzaroma I; Santinelli L; Ceccarelli G; Vullo V; Turriziani O; d'Ettorre G
Curr HIV Res; 2019; 17(3):183-189. PubMed ID: 31490760
[TBL] [Abstract][Full Text] [Related]
14. Increased Intrathecal Immune Activation in Virally Suppressed HIV-1 Infected Patients with Neurocognitive Impairment.
Edén A; Marcotte TD; Heaton RK; Nilsson S; Zetterberg H; Fuchs D; Franklin D; Price RW; Grant I; Letendre SL; Gisslén M
PLoS One; 2016; 11(6):e0157160. PubMed ID: 27295036
[TBL] [Abstract][Full Text] [Related]
15. Elevated sCD163 in plasma but not cerebrospinal fluid is a marker of neurocognitive impairment in HIV infection.
Burdo TH; Weiffenbach A; Woods SP; Letendre S; Ellis RJ; Williams KC
AIDS; 2013 Jun; 27(9):1387-95. PubMed ID: 23435298
[TBL] [Abstract][Full Text] [Related]
16. Central nervous system immune activation characterizes primary human immunodeficiency virus 1 infection even in participants with minimal cerebrospinal fluid viral burden.
Spudich S; Gisslen M; Hagberg L; Lee E; Liegler T; Brew B; Fuchs D; Tambussi G; Cinque P; Hecht FM; Price RW
J Infect Dis; 2011 Sep; 204(5):753-60. PubMed ID: 21844301
[TBL] [Abstract][Full Text] [Related]
17. Interpreting cerebrospinal fluid pleocytosis in HIV in the era of potent antiretroviral therapy.
Marra CM; Maxwell CL; Collier AC; Robertson KR; Imrie A
BMC Infect Dis; 2007 May; 7():37. PubMed ID: 17475004
[TBL] [Abstract][Full Text] [Related]
18. Antiretroviral neuropenetration scores better correlate with cognitive performance of HIV-infected patients after accounting for drug susceptibility.
Fabbiani M; Grima P; Milanini B; Mondi A; Baldonero E; Ciccarelli N; Cauda R; Silveri MC; De Luca A; Di Giambenedetto S
Antivir Ther; 2015; 20(4):441-7. PubMed ID: 25516553
[TBL] [Abstract][Full Text] [Related]
19. CSF inflammatory markers and neurocognitive function after addition of maraviroc to monotherapy darunavir/ritonavir in stable HIV patients: the CINAMMON study.
Barber TJ; Imaz A; Boffito M; Niubó J; Pozniak A; Fortuny R; Alonso J; Davies N; Mandalia S; Podzamczer D; Gazzard B
J Neurovirol; 2018 Feb; 24(1):98-105. PubMed ID: 29280108
[TBL] [Abstract][Full Text] [Related]
20. Soluble CD14 in cerebrospinal fluid is associated with markers of inflammation and axonal damage in untreated HIV-infected patients: a retrospective cross-sectional study.
Jespersen S; Pedersen KK; Anesten B; Zetterberg H; Fuchs D; Gisslén M; Hagberg L; Trøseid M; Nielsen SD
BMC Infect Dis; 2016 Apr; 16():176. PubMed ID: 27103116
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
